SeekingAlpha · Aug 17, 2026
Vera Therapeutics: FDA's eGFR Analysis Supports A Speculative Buy
Vera Therapeutics is upgraded to Buy following TRUTAKNA's FDA approval and encouraging eGFR data. Learn more about VERA stock here.
VE
NASDAQ · VERA
Vera Therapeutics, Inc.
Healthcare · Biotechnology
$32.28
Up+$1.02 (+3.25%)
Updated Aug 22, 2026, 11:06 PM
SID Score
4.0/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 2.94B
- P/E ratio
- -13.44
- Dividend yield
- 0.00%
- 52-week range
- $28.86 – $47.00
- Volume
- 1.29M
- Avg. volume
- 1.59M
Price performance
VERA price history
1M range · 21 trading sessions · Daily adjusted prices
VERA closed at $32.28 after 21 trading sessions, down 8.96% for the selected period.
- Last close
- $32.28
- Period change
- -8.96%
- Period low
- $28.89
- Period high
- $35.45
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $31.42 | $32.97 | $31.0331 | $32.275 | 1.29M |
| Aug 20, 2026 | $32.295 | $32.295 | $30.72 | $31.26 | 1.56M |
| Aug 19, 2026 | $32.88 | $33.48 | $31.70 | $32.275 | 1.26M |
| Aug 18, 2026 | $31.31 | $32.3499 | $31.31 | $32.28 | 1.03M |
| Aug 17, 2026 | $31.30 | $32.72 | $31.10 | $31.63 | 2.75M |
| Aug 14, 2026 | $31.29 | $32.31 | $29.73 | $31.63 | 5.88M |
| Aug 13, 2026 | $29.99 | $30.11 | $28.86 | $28.89 | 1.17M |
| Aug 12, 2026 | $30.74 | $31.18 | $29.71 | $29.99 | 1.68M |
| Aug 11, 2026 | $31.97 | $32.05 | $30.03 | $30.29 | 1.92M |
| Aug 10, 2026 | $32.62 | $32.96 | $31.35 | $31.58 | 1.07M |
| Aug 7, 2026 | $32.81 | $33.0937 | $32.085 | $32.89 | 1.52M |
| Aug 6, 2026 | $30.90 | $32.46 | $30.62 | $32.02 | 1.94M |
| Aug 5, 2026 | $30.35 | $31.08 | $29.54 | $30.35 | 3.21M |
| Aug 4, 2026 | $32.76 | $32.76 | $29.67 | $29.95 | 5.14M |
| Aug 3, 2026 | $31.82 | $32.6699 | $30.8625 | $32.23 | 1.51M |
| Jul 31, 2026 | $32.75 | $32.81 | $31.54 | $32.10 | 1.44M |
| Jul 30, 2026 | $32.70 | $33.395 | $32.285 | $33.05 | 2.28M |
| Jul 29, 2026 | $32.99 | $33.52 | $32.0401 | $32.51 | 1.47M |
| Jul 28, 2026 | $35.00 | $35.17 | $32.76 | $33.32 | 3.02M |
| Jul 27, 2026 | $35.94 | $36.215 | $35.16 | $35.18 | 1.11M |
| Jul 24, 2026 | $36.69 | $36.87 | $35.41 | $35.45 | 786.23K |
Latest VERA news
The latest Smart Investors Daily articles mentioning VERA.
Stock researchCompany · Overview
VERA research
Overview
Company profile and research snapshot.
Company profile
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $73.25
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 17, 2026 | Wedbush | Neutral | — |
| Aug 12, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 11, 2026 | Wedbush | Neutral | — |
| Jul 8, 2026 | TD Cowen | Buy | — |
| Jul 8, 2026 | Guggenheim | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 12, 2026
HC Wainwright & Co. Maintains Buy on Vera Therapeutics, Lowers Price Target to $90
HC Wainwright & Co. analyst Arthur He maintains Vera Therapeutics (NASDAQ:VERA) with a Buy and lowers the price target from $125 to $90.
Benzinga · Aug 11, 2026
Wedbush Maintains Neutral on Vera Therapeutics, Lowers Price Target to $34
Wedbush analyst Laura Chico maintains Vera Therapeutics (NASDAQ:VERA) with a Neutral and lowers the price target from $43 to $34.
Benzinga · Aug 10, 2026
Vera Therapeutics Q2 EPS $(1.52) Beats $(1.61) Estimate
Vera Therapeutics (NASDAQ:VERA) reported quarterly losses of $(1.52) per share which beat the analyst consensus estimate of $(1.61) by 5.59 percent. This is a 26.67 percent decrease over losses of $(1.20) per share from
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
